FDA Delays Camizestrant Breast Cancer Review
Decision brief
Answer first · skim in under a minute
The FDA has delayed the review of AstraZeneca's breast cancer drug, raising questions about the future of the drug and its market impact. Here's what you need to know.
FDA review of AstraZeneca’s breast cancer candidate camizestrant hit a high-stakes checkpoint in 2026. ODAC discussed NDA 220359 on April 30, 2026, after SERENA-6 showed a ctDNA-guided switch strategy in ESR1-mutated HR-positive disease.
Contents9 sections
Key Takeaways
- FDA scheduled ODAC for camizestrant NDA 220359 on April 30, 2026.
- Proposed use: camizestrant plus CDK4/6 inhibitor after emergent ESR1 mutation in 1L HR+/HER2− advanced breast cancer.
- SERENA-6 (NCT04964934) is the pivotal Phase III evidence base published in NEJM.
- Review timelines can move after advisory input and additional FDA data requests.
What did FDA put before ODAC on camizestrant?
FDA’s advisory-committee calendar states that on the morning of April 30, 2026, ODAC would discuss NDA 220359 for camizestrant tablets from AstraZeneca Pharmaceuticals LP.
The proposed indication is combination use with a CDK4/6 inhibitor (palbociclib, ribociclib, or abemaciclib) for adults with HR-positive, HER2-negative locally advanced or metastatic breast cancer upon emergence of an ESR1 mutation during first-line endocrine-based therapy, based on an FDA-approved test. Source: FDA ODAC April 30, 2026 announcement.
What did SERENA-6 show for breast cancer outcomes?
SERENA-6 tested a ctDNA-guided early switch to camizestrant plus continued CDK4/6 inhibition versus continuing aromatase inhibitor plus CDK4/6 inhibitor in patients without radiographic progression.
The NEJM report of the Phase III trial found longer investigator-assessed progression-free survival for the camizestrant switch strategy, with a hazard ratio of 0.44 (95% CI, 0.31 to 0.60). Trial registry: ClinicalTrials.gov NCT04964934. Publication: NEJM SERENA-6 article.
Why can FDA review timelines slip after ODAC?
Advisory-committee discussion often focuses on trial design, clinical meaningfulness of switching before radiographic progression, and residual uncertainties in longer-term endpoints.
When FDA requests additional analyses after an ODAC meeting, the statutory review clock can be extended so reviewers can evaluate the new package. That is the operational meaning of a “delayed review” for BD and forecasting teams, even when the NDA remains under active review rather than withdrawn.
What should European pharma teams watch next?
EU and other regional filings for the same SERENA-6 setting remain commercially relevant if the U.S. decision date moves. Teams should track label language around ESR1 testing, CDK4/6 partner drugs, and whether regulators accept pre-progression molecular switching.
- Confirm local access to validated ESR1 ctDNA tests
- Model revenue timing with a wider U.S. decision window
- Separate ODAC vote optics from final FDA action
Reuters covered the ASCO 2025 SERENA-6 readout, including the reported 56% reduction in risk of progression or death in the camizestrant arm versus continued standard therapy: Reuters SERENA-6 coverage.
What remains unproven for investors?
SERENA-6 established a PFS benefit for the switch strategy in the published dataset. Overall survival maturity, real-world testing logistics, and final FDA labeling remain open items.
Do not treat an ODAC discussion or a review-clock extension as a final approval or rejection. Wait for the FDA action letter and labeled indication text before locking launch models.
Related NovaPharma coverage
- Hayes ESMO breast cancer award 2026
- Owkin–AstraZeneca AI collaboration
- Circulating biomarkers in breast cancer
Frequently Asked Questions
What breast cancer setting is camizestrant under FDA review for?
FDA’s April 30, 2026 ODAC agenda covers NDA 220359 for camizestrant plus a CDK4/6 inhibitor for adults with HR-positive, HER2-negative advanced breast cancer upon emergence of an ESR1 mutation during first-line endocrine-based therapy.
What did SERENA-6 show in the NEJM publication?
In SERENA-6 (NCT04964934), switching to camizestrant with continued CDK4/6 inhibition after ctDNA-detected ESR1 mutation improved progression-free survival versus continuing an aromatase inhibitor plus CDK4/6 inhibitor, with a reported hazard ratio of 0.44 (95% CI 0.31–0.60).
Does an ODAC discussion mean FDA rejected the drug?
No. ODAC advice is non-binding. FDA still completes its own review of NDA 220359. Companies and FDA may also request or provide additional analyses that extend the review clock.
Primary Sources
AstraZeneca pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
Deeper reading
Industry reports & whitepapers
- Radiation Therapy: Fractionation, Image-Guidance, and Special Services (Idaho Only) — This policy outlines medically necessary radiation therapy protocols for conditions like breast canc…